1. Home
  2. NVAX vs LMAT Comparison

NVAX vs LMAT Comparison

Compare NVAX & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • LMAT
  • Stock Information
  • Founded
  • NVAX 1987
  • LMAT 1983
  • Country
  • NVAX United States
  • LMAT United States
  • Employees
  • NVAX N/A
  • LMAT N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • LMAT Medical/Dental Instruments
  • Sector
  • NVAX Health Care
  • LMAT Health Care
  • Exchange
  • NVAX Nasdaq
  • LMAT Nasdaq
  • Market Cap
  • NVAX 2.0B
  • LMAT 2.0B
  • IPO Year
  • NVAX 1995
  • LMAT 2006
  • Fundamental
  • Price
  • NVAX $9.76
  • LMAT $89.08
  • Analyst Decision
  • NVAX Buy
  • LMAT Buy
  • Analyst Count
  • NVAX 6
  • LMAT 6
  • Target Price
  • NVAX $17.83
  • LMAT $92.60
  • AVG Volume (30 Days)
  • NVAX 7.2M
  • LMAT 98.3K
  • Earning Date
  • NVAX 11-07-2024
  • LMAT 10-31-2024
  • Dividend Yield
  • NVAX N/A
  • LMAT 0.72%
  • EPS Growth
  • NVAX N/A
  • LMAT 47.83
  • EPS
  • NVAX N/A
  • LMAT 1.67
  • Revenue
  • NVAX $987,667,000.00
  • LMAT $205,621,000.00
  • Revenue This Year
  • NVAX N/A
  • LMAT $15.01
  • Revenue Next Year
  • NVAX N/A
  • LMAT $9.07
  • P/E Ratio
  • NVAX N/A
  • LMAT $54.11
  • Revenue Growth
  • NVAX N/A
  • LMAT 16.06
  • 52 Week Low
  • NVAX $3.53
  • LMAT $45.96
  • 52 Week High
  • NVAX $23.86
  • LMAT $93.32
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 36.20
  • LMAT 55.00
  • Support Level
  • NVAX $9.52
  • LMAT $84.69
  • Resistance Level
  • NVAX $10.63
  • LMAT $92.84
  • Average True Range (ATR)
  • NVAX 0.57
  • LMAT 2.05
  • MACD
  • NVAX -0.12
  • LMAT -0.07
  • Stochastic Oscillator
  • NVAX 9.97
  • LMAT 75.21

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Share on Social Networks: